Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's Anticancer Drug Screen

Drug Metabolism and Disposition

Volumn 32, Issue 3, 2004, Pages 321-327

  Gunnarsdottir, Sjofn ^a   Elfarra, Adnan A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 ACETYLVINYLTHIO)GUANINE; 6 (2 ACETYLVINYLTHIO)PURINE; 6 [(7 NITRO 2,1,3 BENZOXADIAZOL 4 YL)THIO] 9H PURIN 2 AMINE; GLUTATHIONE; MERCAPTOPURINE; TIOGUANINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER INHIBITION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DATABASES, GENETIC; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE; HUMANS; LETHAL DOSE 50; NATIONAL INSTITUTES OF HEALTH (U.S.); PRODRUGS; PURINES; RATS; STEREOISOMERISM; THIOGUANINE; UNITED STATES;

ANIMALIA;

EID: 1342281164     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.3.321     Document Type: Article

References (30)

1. Burchenal JH, Murphy ML, Ellison RR, Sykes MP, Tan TC, Leone LA, Karnofsky DA, Craver LF, Dargeon HW, and Rhoads CP (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine in the treatment of leukemia and allied diseases. Blood 8:965-999.
2. Clarke DA, Elion GB, Hitchings GH, and Stock CC (1958) Structure-activity relationships among purines related to 6-mercaptopurine. Cancer Res 18:445-456.
3. Coffey RNT, Watson RWG, Hegarty NJ, O'Neill A, Gibbons N, Brady HR, and Fitzpatrick JM (2000) Thiol-mediated apoptosis in prostate carcinoma cells. Cancer 88:2092-2104.
4. Davis W Jr, Ronai Z, and Tew KD (2001) Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 296:1-6.
5. Elfarra AA, Duescher RJ, Hwang IY, Sicuri AR, and Nelson JA (1995) Targeting 6-thioguanine to the kidney with S-(guanin-6-yl)-L-cysteine. J Pharmacol Exp Ther 274:1298-1304.
6. Elion GB (1989) The purine path to chemotherapy. Science (Wash DC) 244:41-47.
7. Elion GB, Bieber S, and Hitchings GH (1960) A summary of investigations with 2-amino-6-(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in animals. Cancer Chemother Rep 8:36-43.
8. Frank W and Tornyos K (1962) The effectiveness of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in metastatic squamous cell carcinoma of the oropharynx and larynx. Cancer Chemother Rep 20:113-115.
9. Gunnarsdottir S (2002) Glutathione-Dependent Prodrugs of 6-Mercaptopurine and 6-Thioguanine: Characterization and Evaluation as Potential Chemotherapeutic Agents. Ph.D. thesis, University of Wisconsin-Madison, Madison, WI.
10. Gunnarsdottir S and Elfarra AA (2003) Distinct tissue distribution of metabolites of the novel glutathione-activated thiopurine prodrugs cis-6-(2-acetylvinylthio)purine and trans-6-(2-acetylvinylthio)guanine and 6-thioguanine in the mouse. Drug Metab Dispos 31:718-726.
11. Gunnarsdottir S, Rucki M, and Elfarra AA (2002a) Novel glutathione-dependent thiopurine prodrugs: evidence for enhanced cytotoxicity in tumor cells and for decreased bone marrow toxicity in mice. J Pharmacol Exp Ther 301:77-86.
12. Gunnarsdottir S, Rucki M, Phillips LA, Young KM, and Elfarra AA (2002b) The glutathione-activated thiopurine prodrugs trans-6-(2-acetylvinylthio) guanine and cis-6-(2-acetylvinylthio)purine cause less in vivo toxicity than 6-thioguanine after single- and multiple-dose regimens. Mol Cancer Ther 1:1211-1220.
13. Hartmann JT and Bokemeyer C (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19:1541-1543.
14. Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, and Cerny T (1998) Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol 70:176-182.
15. Lash LH, Shivnani A, Mai J, Chinnaiyan P, Krause RJ, and Elfarra AA (1997) Renal cellular transport, metabolism, and cytotoxicity of S-(6-purin)glutathione, a prodrug of 6-mercapto-purine and analogues. Biochem Pharmacol 54:1341-1349.
16. Lusini L, Tripodi SA, Rossi R, Giannerini F, Giustarini D, Del Vecchio MT, Barbanti G, Cintorino M, Tosi P, and Di Simplicio P (2001) Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 91:55-59.
17. Mekhail-Ishak K, Hudson N, Tsao MS, and Batist G (1989) Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res 49:4866-4869.
18. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines in culture. J Natl Cancer Inst 83:757-766.
19. Monks A, Scudiero DA, Johnson GS, Paull KD, and Sausville EA (1997) The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Design 12:533-541.
20. Moore GE, Bross IDJ, Ausman R, Nadler S, Jones R Jr, Slack N, and Rimm AA (1968) Effects of 6-mercaptopurine (NSC-755) in 290 patients with advanced cancer. Cancer Chemother Rep 52:655-660.
21. Motzer RJ and Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417.
22. 6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 59:629-636.
23. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092.
24. Perry RR, Mazetta J, Levin M, and Barranco SC (1993) Glutathione levels and variability in breast tumor and normal tissue. Cancer 72:783-787.
25. Piccart MJ, Lamb H, and Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12:1195-1203.
26. Regelson W, Holland JF, Frei E III, Gold GL, Hall T, Krant M, and Miller SO (1964) Comparative clinical toxicity of 6-mercaptopurine (NSC-755) and 6-mercaptopurine ribonucleoside (NSC-4911) administered intravenously to patients with advanced cancer. Cancer Chemother Rep 36:41-48.
27. Skipper HE, Thomson JR, Elion GB, and Hitchings GH (1954) Observations on the anticancer activity of 6-mercaptopurine. Cancer Res 14:294-298.
28. Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB, and Schmidt DE Jr (1996) Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 50:149-159.
29. 2 cells through rapid depletion of intracellular thiols. Arch Biochem Biophys 374:142-152.
30. Yang CF, Shen HM, and Ong CM (2000b) Intracellular thiol depletion causes mitochondrial permeability transition in ebselen-induced apoptosis. Arch Biochem Biophys 380:319-330.